Systemic corticosteroid use and sino-nasal surgery (pooled analysis)

In a pooled analysis of the two trials (up to week 24 for SINUS-24 and up to week 52 for SINUS-52), DUPIXENT® significantly reduced systemic corticosteroid use or the need for sino-nasal surgery vs. placebo + INCS over the 52-week period1,3

Kaplan Meier graph showing the time to first systemic corticosteroid use and/or sino-nasal surgery during the treatment period in a pooled analysis of SINUS-24 and SINUS-52 (up to Week 24 for SINUS-24 and up to Week 52 for SINUS-52). Overall, DUPIXENT treatment led to a 76% reduction in systemic corticosteroid use or need for sino-nasal surgery with a hazard ratio of 0.24 and 95% confidence internal of 0.17 to 0.35. The percentage of patients requiring rescue with systemic corticosteroids or nasal polyp surgery was 10% for DUPIXENT® (42 out of 438 patients) versus 34% for placebo (97 out of 286 patients).

In the pooled analysis, over the 52-week period, proportions of patients who required:

Systemic corticosteroid use: 12.3% (DUPIXENT®), 38% (placebo)1

Sino-nasal surgery: 1.2% (DUPIXENT®), 10.2% (placebo)1

Connect With a Rep

Have questions about DUPIXENT®? Get answers from a representative.

Freedom support program logo.

Freedom Support Program

Find out what the Freedom Support Program can bring to your patients and how you can help them access it.



DUPIXENT®, Sanofi and Freedom logos are trademarks of Sanofi, used under license by sanofi-aventis Canada Inc.
REGENERON® is a trademark of Regeneron Pharmaceuticals, Inc. All rights reserved.
© 2023 sanofi-aventis Canada Inc. All rights reserved.

MAT-CA-2300229E
Last updated: 06/2023

paab logo